A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 13, 2017

Primary Completion Date

August 25, 2020

Study Completion Date

August 25, 2020

Conditions
Advanced Renal Cell Carcinoma
Interventions
DRUG

Cabozantinib

Cabozantinib tablets

Trial Locations (19)

Unknown

Nagoya University Hospital, Nagoya

Hokkaido University Hospital, Sapporo

Sapporo Medical University Hospital, Sapporo

Kobe University Hospital, Kobe

Yokohama City University Hospital, Yokohama

Yokohama City University Medical Center, Yokohama

Kindai University Hospital, Sayama

Osaka University Hospital, Suita

Nippon Medcal School Hospital, Bunkyo-ku

Toranomon Hospital, Minato-ku

Keio University Hospital, Shinjuku-ku

Tokyo Women's Medical University Hospital, Shinjuku-ku

Kyushu University Hospital, Fukuoka

Niigata University Medical and Dental Hospital, Niigata

Okayama University Hospital, Okayama

Osaka City University Hospital, Osaka

Osaka International Cancer Institute, Osaka

Tokushima University Hospital, Tokushima

Yamagata University Hospital, Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT03339219 - A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter